Table 1– Patients’ characteristics, comorbidities, medication, pharmacokinetic parameters and outcomes

Patient	Age yrs	Sex	Weight kg	BMI kg·m⁻²	TB	Comorbidity	Anti-TB drugs	Treatment time days	C_max mg·L⁻¹	T_max h	AUC₂₄ mg·h·L⁻¹	Final outcome
1	41	M	105	33.5	MDR	Diabetes	Rfb, Z, Cm, Mfx, Eto, Cs	696	6.94	2.5	51.14	Cured
2	58	M	61	21.6	XDR	COPD	Cm, Mfx, Eto, Cs, PAS	83	6.44	2.5	52.79	Died while on treatment (COPD exacerbation)
3	39	M	92	30	MDR	Diabetes	Z, Cm, Mfx, Eto, Cs	425	5.77	2	52.78	Cured
4	29	M	86	26	XDR		Rfb, Z, Cm, Mfx, Eto, Cs	365	2.49	3	24.04	Failed
5	26	F	52	20.6	XDR		E, Cm, Mfx, Eto, Cs	8	1.32	3	9.17	Died while on treatment (suicide)
6	64	M	69	23.9	MDR	Peptic cancer	E, Cm, Mfx, Eto, Cs	81	4.38	2	37.29	Still on treatment, improved
7	24	F	44	17.6	MDR	CF	Rfb, Am, Mfx, Eto, Lzd, Ipm/Cln	51	4.81	1.5	38.54	Still on treatment, improved

BMI: body mass index; TB: tuberculosis; C_max: maximal concentration; T_max: time at which C_max reached; AUC₂₄: area under the concentration–time curve up to 24 h post-dosage; M: male; F: female; MDR: multidrug-resistant; XDR: extensively drug-resistant; COPD: chronic obstructive pulmonary disease; CF: cystic fibrosis; Rfb: rifabutin; Z: pyrazinamide; Cm: capreomycin; Mfx: moxifloxacin; Eto: ethionamide; Cs: cycloserine; PAS: para-aminosalicylic acid; E: ethambutol; Am: amikacin; Lzd: linezolid; Ipm/Cln: imipenem/cilastatin.